|
Caspofungin (INN〔(European Medicines Agency's list of authorised medicines for human use (C) )〕) (brand name Cancidas worldwide) is a lipopeptide antifungal drug from Merck & Co., Inc. discovered by James Balkovec, Regina Black and Frances A. Bouffard.〔(【引用サイトリンク】website=https://www.google.com/patents/US5378804?dq=5378804&hl=en&sa=X&ei=pHIJVZntI4uWNpStg6gK&ved=0CB0Q6AEwAA )〕 It is a member of a new class of antifungals termed the echinocandins. It works by inhibiting the enzyme (1→3)-β-D-glucan synthase and thereby disturbing the integrity of the fungal cell wall. Caspofungin was the first inhibitor of fungal (1→3)-β-D-glucan synthesis to be approved by the United States Food and Drug Administration. Caspofungin is administered intravenously. ==Spectrum of fungal susceptibility and resistance== Caspofungin has been effective in treating fungal infections caused by ''Aspergillus'' and ''Candida'' species. The following represents MIC susceptibility for a few medically significant organisms.〔http://www.toku-e.com/Assets/MIC/Caspofungin%20acetate.pdf〕 * ''Candida albicans'' 0.015 - 16 μg/ml * ''Candida krusei'' 0.03 - 8 μg/ml * ''Cryptococcus neoformans'' 16 μg/ml 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「caspofungin」の詳細全文を読む スポンサード リンク
|